High-grade meningiomas: New avenues for drug treatment?

Current Opinion in Neurology

Volumn 26, Issue 6, 2013, Pages 708-715

  Preusser, Matthias ^a   Berghoff, Anna S ^a   Hottinger, Andreas F ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Anaplastic; Atypical; Drug therapy; Meningioma; Targeted drugs

Indexed keywords

CYTOTOXIC AGENT; MAMMALIAN TARGET OF RAPAMYCIN; PLATELET DERIVED GROWTH FACTOR; TRABECTEDIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT;

ANTIANGIOGENIC ACTIVITY; DISEASE CONTROL; HISTOLOGY; HUMAN; IMMUNOTHERAPY; IN VITRO STUDY; LOCAL THERAPY; MENINGIOMA; REVIEW; UPREGULATION; DRUG EFFECTS; GENETICS; HISTORY; MENINGEAL NEOPLASMS; SIGNAL TRANSDUCTION;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; HISTORY, 20TH CENTURY; HUMANS; MENINGEAL NEOPLASMS; MENINGIOMA; SIGNAL TRANSDUCTION;

EID: 84892365280     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0000000000000035     Document Type: Review

References (69)

1. Rausing A, Ybo W, Stenflo J. Intracranial meningioma - A population study of ten years. Acta Neurol Scand 1970; 46:102-110.
2. Klaeboe L, Lonn S, Scheie D, et al. Incidence of intracranial meningiomas in Denmark, Finland, Norway and Sweden, 1968-1997. Int J Cancer 2005; 117:996-1001.
3. Maier H, Ofner D, Hittmair A, et al. Classic, atypical, and anaplastic meningioma: Three histopathological subtypes of clinical relevance. J Neurosurg 1992; 77:616-623.
4. Harrison MJ, Wolfe DE, Lau TS, et al. Radiation-induced meningiomas: Experience at the Mount Sinai Hospital and review of the literature. J Neurosurg 1991; 75:564-574.
5. Perry A, Louis D, Scheithauer B, et al. Meningiomas. Louis B, Ohgaki H, Wiestler O, Cavenee W, editors., 4th ed. Lyon, France: IARC Press; 2007.
6. Braganza MZ, Kitahara CM, Berrington de Gonzalez A, et al. Ionizing radiation and the risk of brain and central nervous system tumors: A systematic review. Neuro Oncol 2012; 14:1316-1324.
7. .Claus EB, Calvocoressi L, Bondy ML, et al. Dental X-rays and risk of meningioma. Cancer 2012; 118:4530-4537.
8. Louis DN, Ramesh V, Gusella JF. Neuropathology and molecular genetics of neurofibromatosis 2 and related tumors. Brain Pathol 1995; 5:163-172.
9. Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 1993; 363:515-521.
10. Wellenreuther R, Waha A, Vogel Y, et al. Quantitative analysis of neurofibromatosis type 2 gene transcripts in meningiomas supports the concept of distinct molecular variants. Lab Invest 1997; 77:601-606.
11. Korhonen K, Salminen T, Raitanen J, et al. Female predominance in meningiomas can not be explained by differences in progesterone, estrogen, or androgen receptor expression. J Neurooncol 2006; 80:1-7.
12. Wiedmann M, Brunborg C, Lindemann K, et al. Body mass index and the risk of meningioma, glioma and schwannoma in a large prospective cohort study (The HUNT Study). Br J Cancer 2013; 19:289-294.
13. Claus EB, Calvocoressi L, Bondy ML, et al. Exogenous hormone use, reproductive factors, and risk of intracranial meningioma in females. J Neurosurg 2013; 118:649-656.
14. Alvernia JE, Dang ND, Sindou MP. Convexity meningiomas: Study of recurrence factors with special emphasis on the cleavage plane in a series of 100 consecutive patients. J Neurosurg 2011; 115:491-498.
15. van Alkemade H, de Leau M, Dieleman EM, et al. Impaired survival and longterm neurological problems in benign meningioma. Neuro Oncol 2012; 14:658-666.
16. Durand A, Labrousse F, Jouvet A, et al. WHO grade II and III meningiomas: A study of prognostic factors. J Neurooncol 2009; 95:367-375.
17. Louis DN, Ohgaki H, Wistler OD, Cavanee WK, editors. WHO classification of tumours of the central nervous system. Lyon, France: IARC Press; 2007.; p. 164.
18. Backer-Grondahl T, Moen BH, Torp SH. The histopathological spectrum of human meningiomas. Int J Clin Exp Pathol 2012; 5:231-242.
19. Schweizer L, Koelsche C, Sahm F, et al. Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein. Acta Neuropathol 2013; 125:651- 658.
20. Nagaishi M, Nobusawa S, Tanaka Y, et al. Slug, twist, and E-cadherin as immunohistochemical biomarkers in meningeal tumors. PLoS One 2012; 7:e46053.
21. Alahmadi H, Croul SE. Pathology and genetics of meningiomas. Semin Diagn Pathol 2011; 28:314-324.
22. Jaskolski DJ, Gresner SM, Zakrzewska M, et al. Molecular alterations in meningiomas: Association with clinical data. Clin Neuropathol 2013; 32:114-121.
23. Jansen M, Mohapatra G, Betensky RA, et al. Gain of chromosome arm 1q in atypical meningioma correlates with shorter progression-free survival. Neuropathol Appl Neurobiol 2012; 38:213-219.
24. Perez-Magan E, Campos-Martin Y, Mur P, et al. Genetic alterations associated with progression and recurrence in meningiomas. J Neuropathol Exp Neurol 2012; 71:882-893.
25. Gauchotte G, Vigouroux C, Rech F, et al. Expression of minichromosome maintenance MCM6 protein in meningiomas is strongly correlated with histologic grade and clinical outcome. Am J Surg Pathol 2012; 36:283-291.
26. Chamberlain MC, Tsao-Wei DD, Groshen S. Temozolomide for treatmentresistant recurrent meningioma. Neurology 2004; 62:1210-1212.
27. Kliese N, Gobrecht P, Pachow D, et al. miRNA-145 is downregulated in atypical and anaplastic meningiomas and negatively regulates motility and proliferation of meningioma cells. Oncogene 2013; 39:4712-4720. [Epub ahead of print].
28. Preusser M, Hassler M, Birner P, et al. Microvascularization and expression of VEGF and its receptors in recurring meningiomas: Pathobiological data in favor of antiangiogenic therapy approaches. Clin Neuropathol 2012; 31:352-360.
29. Brastianos PK, Horowitz PM, Santagata S, et al. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet 2013; 45:285-289.
30. Clark VE, Erson-Omay EZ, Serin A, et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 2013; 339:1077-1080.
31. Stafford SL, Perry A, Suman VJ, et al. Primarily resected meningiomas: Outcome and prognostic factors in 581 Mayo Clinic patients, 1978 through 1988. Mayo Clin Proc 1988; 73:936-942.
32. Tanzler E, Morris CG, Kirwan JM, et al. Outcomes of WHO Grade I meningiomas receiving definitive or postoperative radiotherapy. Int J Radiat Oncol Biol Phys 2011; 79:508-513.
33. Johnson WD, Loredo LN, Slater JD. Surgery and radiotherapy: Complementary tools in the management of benign intracranial tumors. Neurosurg Focus 2008; 24:E2.
34. Glaholm J, Bloom HJ, Crow JH. The role of radiotherapy in the management of intracranial meningiomas: The Royal Marsden Hospital experience with 186 patients. Int J Radiat Oncol Biol Phys 1990; 18:755-761.
35. Mair R, Morris K, Scott I, Carroll TA. Radiotherapy for atypical meningiomas. J Neurosurg 2011; 115:811-819.
36. Mendenhall WM, Morris CG, Amdur RJ, et al. Radiotherapy alone or after subtotal resection for benign skull base meningiomas. Cancer 2003; 98:1473-1482.
37. Korah MP, Nowlan AW, Johnstone PA, Crocker IR. Radiation therapy alone for imaging defined meningiomas. Int J Radiat Oncol Biol Phys 2010; 76:181- 186.
38. Chamberlain MC. Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma. J Neurooncol 2012; 107:315-321.
39. Hahn BM, Schrell UM, Sauer R, et al. Prolonged oral hydroxyurea and concurrent 3D-conformal radiation in patients with progressive or recurrent meningioma: Results of a pilot study. J Neurooncol 2005; 74:157-165.
40. Lou E, Sumrall AL, Turner S, et al. Bevacizumab therapy for adults with recurrent/progressive meningioma: A retrospective series. J Neurooncol 2012; 109:63-70.
41. Nayak L, Iwamoto FM, Rudnick JD, et al. Atypical and anaplastic meningiomas treated with bevacizumab. J Neurooncol 2012; 109:187-193.
42. Kaley TJ, Wen PY, Schiff D, et al. Phase II trial of sunitinib (SU011248) for recurrent meningioma. Neuro Oncol 2010; 12 (Suppl4):iv69-iv77.
43. Wen PY, Yung WK, Lamborn KR, et al. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01- 08). Neuro Oncol 2009; 11:853-860.
44. Reardon DA, Norden AD, Desjardins A, et al. Phase II study of Gleevec(R) plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. J Neurooncol 2012; 106:409-415.
45. Norden AD, Raizer JJ, Abrey LE, et al. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol 2010; 96:211-217.
46. de Robles P, McIntyre J, Kalra S, et al. Methylation status of MGMT gene promoter in meningiomas. Cancer Genet Cytogenet 2008; 187:25-27.
47. Gupta V, Su YS, Samuelson CG, et al. Irinotecan: A potential new chemotherapeutic agent for atypical or malignant meningiomas. J Neurosurg 2007; 106:455-462.
48. Chamberlain MC, Tsao-Wei DD, Groshen S. Salvage chemotherapy with CPT-11 for recurrent meningioma. J Neurooncol 2006; 78:271-276.
49. Schrell UM, Rittig MG, Anders M, et al. Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. J Neurosurg 1997; 86:840-844.
50. Newton HB, Slivka MA, Stevens C. Hydroxyurea chemotherapy for unresectable or residual meningioma. J Neurooncol 2000; 49:165-170.
51. Chamberlain MC, Johnston SK. Hydroxyurea for recurrent surgery and radiation refractory meningioma: A retrospective case series. J Neurooncol 2011; 104:765-771.
52. Lamszus K, Lengler U, Schmidt NO, et al. Vascular endothelial growth factor, hepatocyte growth factor/scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy. Neurosurgery 2000; 46:938-947.
53. Provias J, Claffey K, delAguila L, et al. Meningiomas: Role of vascular endothelial growth factor/vascular permeability factor in angiogenesis and peritumoral edema. Neurosurgery 1997; 40:1016-1026.
54. Pfister C, Pfrommer H, Tatagiba MS, Roser F. Vascular endothelial growth factor signals through platelet-derived growth factor receptor beta in meningiomas in vitro. Br J Cancer 2012; 107:1702-1713.
55. Nassehi D, Dyrbye H, Andresen M, et al. Vascular endothelial growth factor A protein level and gene expression in intracranial meningiomas with brain edema. APMIS 2011; 119:831-843.
56. Ando H, Natsume A, Iwami K, et al. A hypoxia-inducible factor (HIF)-3alpha splicing variant, HIF-3alpha4 impairs angiogenesis in hypervascular malignant meningiomas with epigenetically silenced HIF-3alpha4. Biochem Biophys Res Commun 2013; 433:139-144.
57. Puchner MJ, Hans VH, Harati A, et al. Bevacizumab-induced regression of anaplastic meningioma. Ann Oncol 2010; 21:2445-2446.
58. Andrae N, Kirches E, Hartig R, et al. Sunitinib targets PDGF-receptor and Flt3 and reduces survival and migration of human meningioma cells. Eur J Cancer 2012; 48:1831-1841.
59. Ragel BT, Jensen RL. Aberrant signaling pathways in meningiomas. J Neurooncol 2010; 99:315-324.
60. Johnson MD, Okedli E, Woodard A, et al. Evidence for phosphatidylinositol 3-kinase-Aktp7S6K pathway activation and transduction of mitogenic signals by platelet-derived growth factor in meningioma cells. J Neurosurg 2002; 97:668-675.
61. Johnson MD, Woodard A, Kim P, Frexes-Steed M. Evidence for mitogenassociated protein kinase activation and transduction of mitogenic signals by platelet-derived growth factor in human meningioma cells. J Neurosurg 2001; 94:293-300.
62. Carroll RS, Black PM, Zhang J, et al. Expression and activation of epidermal growth factor receptors in meningiomas. J Neurosurg 1997; 87:315-323.
63. Chamberlain MC, Barnholtz-Sloan JS. Medical treatment of recurrent meningiomas. Expert Rev Neurother 2011; 11:1425-1432.
64. Pachow D, Andrae N, Kliese N, et al.mTORC1 inhibitors suppress meningioma growth in mouse models. Clin Cancer Res 2013; 19:1180-1189.
65. D'Incalci M, Galmarini CM. A review of trabectedin (ET-743): A unique mechanism of action. Mol Cancer Ther 2010; 9:2157-2163.
66. Germano G, Frapolli R, Belgiovine C, et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell 2013; 23:249-262.
67. Preusser M, Spiegl-Kreinecker S, Lotsch D, et al. Trabectedin has promising antineoplastic activity in high-grade meningioma. Cancer 2012; 118:5038- 5049.
68. Okada H, Kalinski P, Ueda R, et al. Induction of CD8 T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic- polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 2011; 29:330-336.
69. Andersen BM, Pluhar GE, Seiler CE, et al. Vaccination for invasive canine meningioma induces in situ production of antibodies capable of antibodydependent cell-mediated cytotoxicity. Cancer Res 2013; 73: 2987-2997.